SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors demonstrate substantial potential in mitigating cardiovascular risks and improving long-term renal outcomes.8,9 The EMPA-REG OUTCOME trial first reported the CV benefits of Empagliflozin in type 2 diabetic mellitus (T2DM) patients, demonstrating a notable decrease in CV death.10 Subsequently, there has been a surge of interest in SGLT-2 inhibitors.